Anagram Therapeutics Expands Leadership Team to Accelerate Development of ANG003 and Pipeline of Orally Delivered Enzyme Therapies for Rare Diseases

FOR IMMEDIATE RELEASE Anagram Therapeutics Expands Leadership Team to Accelerate Development of ANG003 and Pipeline of Orally Delivered Enzyme Therapies for Rare Diseases NATICK, Mass., March 6, 2026 — Anagram Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases, today announced three senior leadership appointments reflecting the company's clinical progress: Evan Bailey, MD, joins as Chief Medical OQicer; Tim CaQrey as Vice President of Finance; and Hugh Wight has been promoted to Chief Operating OQicer. Together, these changes represent a major expansion of Anagram’s leadership team as the company makes significant progress advancing ANG003, a novel orally delivered recombinant enzyme therapy for people with cystic fibrosis and exocrine pancreatic insuQiciency (EPI), alongside a broader rare disease pipeline. "We are thrilled to welcome Evan and Tim to Anagram and to recognize Hugh's contributions with this expanded role. Each bring expertise that will be instrumental as we accelerate ANG003 and expand our rare disease pipeline," said Robert Gallotto, founder and Chief Executive Officer of Anagram. "Their additions to our leadership team reflect the meaningful progress we are making toward delivering transformative orally delivered enzyme therapies to patients with significant unmet needs and position Anagram for long-term strategic growth." Evan Bailey, MD, a pediatric pulmonologist by training, has spent his career at the forefront of cystic fibrosis medicine. Dr. Bailey served as Medical Director at Vertex Pharmaceuticals, where he led the 2019 U.S. launch of TRIKAFTA® for the treatment of CF before serving as Global Medical Lead for the CF pipeline. He most recently served as Chief Medical OQicer of Applied Therapeutics. Earlier in his career, Dr. Bailey was Assistant Professor of Pediatrics at the University of Massachusetts Medical School, where he was a principal investigator for multiple clinical trials running both the CF clinical and research programs. He completed his residency and fellowship training at Boston Children's Hospital and holds an MD from Loyola University Chicago Stritch School of Medicine. Dr. Bailey obtained an MA in Medical Sciences from the Boston University School of Medicine and a Bachelor of Science in Chemistry and French from Boston College. Tim Caffrey is a finance and operations executive with more than 15 years of experience in biotech and other industries, with expertise in financial strategy, FP&A, IPO readiness, reporting systems, and compliance. He joins Anagram from Neurogastrx, a clinical-stage biopharmaceutical company focused on gastrointestinal diseases, where he served as Vice President of Finance. Previously, he held positions of increasing responsibility at Concert Pharmaceuticals, including Director, Corporate Controller. Tim began his career in Ernst & Young’s commercial audit practice and is a licensed certified public accountant in Massachusetts. He holds a Master’s degree in Accounting from Bentley University’s McCallum Graduate School of Business and a Juris Doctor from Northeastern University. -- more -- Hugh Wight has been with Anagram since 2023, most recently serving as Chief of Corporate Development before his promotion to Chief Operating Officer. He brings more than 30 years of experience advancing biologic and small-molecule programs from early development through marketing authorization, with expertise in building operational frameworks that enable complex drug development. At Anagram, Hugh has been instrumental in developing a global manufacturing program for what could be the world’s first orally delivered recombinant pancreatic enzyme. Prior to joining Anagram, he held roles of increasing responsibility at Allena Pharmaceuticals, Alcresta Therapeutics, Alnara Pharmaceuticals, Altus Pharmaceuticals, and Alkermes, contributing to multiple development and commercialization efforts across enzyme therapies and metabolic disease programs. Hugh received a Bachelor of Science in Microbiology from the University of Maine. About ANG003, Malabsorption Syndromes and Nutrient Metabolism Disorders ANG003 is Anagram’s lead product for the treatment of malabsorption and exocrine pancreatic insuQiciency (EPI). ANG003 is a new class of broad-spectrum recombinant digestive enzyme replacement therapy, targeting some of the most challenging diseases in infants, children, and adults. ANG003 was engineered to be stable and immediately active in the gastrointestinal tract to maximize digestion and absorption. ANG003 contains lipase for fat malabsorption, protease for protein malabsorption, and amylase for carbohydrate malabsorption. People with EPI are currently treated with pancreatic enzyme replacement therapies (PERT) from pig pancreas glands that have a high treatment burden for patients, requiring 15-40 capsules per day. Pig-derived PERT require a significant amount of plastic coating to prevent it from being degraded in the stomach. PERT derived from pig pancreas glands continue to experience global product shortages. The current U.S. PERT market is approximately $2 billion annually. About Anagram Therapeutics Anagram Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of serious diseases caused by malabsorption syndromes and nutrient metabolism disorders, a group of conditions caused by enzyme deficiencies or genetic disorders that prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. The company is leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can have a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. ANG003, Anagram’s lead product for the treatment of malabsorption and exocrine pancreatic insuQiciency, is a new class of broad-spectrum digestive enzyme replacement therapy in clinical trials in people with cystic fibrosis and exocrine pancreatic insuQiciency. Anagram is a privately held company headquartered in Natick, MA. To learn more, visit www.anagramtx.com or follow us on LinkedIn and X/Twitter. # # # Anagram Contact: Media Contact: Kathryn Kilroy Gina Cella Director, Operations Cella Communications [email protected] [email protected] (617) 466-3823 (781) 799-3137 (mobile)

The release as fetched from its publisher. anagramtx.com ↗